Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease

Significant reduction in cardiovascular mortality and all-cause mortality for CCTA coupled with FFRCT versus CCTA alone

MOUNTAIN VIEW, Calif. – August 26, 2023 —Two-year results from FISH&CHIPS, a real world, multi-center, retrospective clinical study with 90,553 patients conducted by the National Health Service (NHS) England were presented at the 2023 European Society of Cardiology (ESC) Congress meeting in Amsterdam by Principal Investigator, Dr. Tim Fairbairn, Consultant Cardiologist, Liverpool Heart and Chest Hospital.

FFRCT (CCTA-derived Fractional Flow Reserve) is part of a clinical pathway for evaluation and diagnosis of coronary artery disease (CAD) that provides clear insight into a patient’s condition with a patient-specific visual model of the heart’s blood flow, helping physicians make more accurate diagnoses and treatment decisions.

The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:

  • A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.
  • An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
  • A 14% relative reduction in additional non-invasive heart testing following CCTA.
  • High prognostic value for FFRCT whereby patients with severely abnormal FFRCT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFRCT values.


“The foresight and continued leadership of NHS England in challenging the status quo and implementing new approaches like the CCTA+FFRCT pathway has a widespread impact on the industry globally,” said Campbell Rogers, Chief Medical Officer, HeartFlow. “The nationwide CCTA-first approach for evaluating patients with possible cardiovascular disease has become the model of both clinical efficacy and efficiency, which is why clinical guidelines across the globe have adopted it. FISH&CHIPS demonstrates that NHS England’s decision to incorporate the HeartFlow FFRCT Analysis into that pathway extended the lives of many English patients and ensured efficient and effective use of noninvasive and invasive testing and treatment.”

“At NIHR Clinical Research Network North West Coast (CRN NWC), we are delighted to see these impressive results from the FISH&CHIPS study, which shows that the introduction of a new health technology, FFRCT, at a national level was associated with a reduction in cardiovascular death and invasive angiography,” said Professor Enitan Carrol, Clinical Director, Clinical Research Network: North West Coast. “The study was funded by the MRC, which followed on from CRN NWC capacity building support for Dr. Fairbairn as a Research Scholar between 2017 and 2019.”

Building on results seen in the recent Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) Trial, which compared a non-invasive Precision Pathway to Traditional Testing, proved the CCTA+FFRCT pathway to be a more effective path in guiding and informing treatment. FISH&CHIPS confirms and extends these results at a population level, delivering marked improvements in the hard clinical endpoints of all-cause and CV mortality, extending patients’ lives without adversely impacting other clinical events.

Additionally, the data reinforce observations from 3-year follow-up of the ADVANCE-DK registry, including the value of attaining FFRCT information early to assess patient risk effectively, and the relationship between lower FFRCT values and increased patient risk.


FISH&CHIPS is a real world, multi-center, retrospective clinical study designed to assess at a national level the incremental impact of adding FFRCT to a CCTA-first diagnostic paradigm for coronary artery disease. The two-year study analyzed data from twenty-five hospital sites in England including 90,553 patients. The primary objective is to determine whether a CCTA and FFRCT diagnostic pathway reduces health-related events, time to diagnosis, and overall healthcare costs compared to a ‘standard of care’ CCTA diagnostic chest pain pathway. The study was funded by the UK Medical Research Council (MRC).

About HeartFlow

HeartFlow is transforming precision coronary care with the only non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guidelines, HeartFlow continues to advance the diagnosis and management of CAD. Our suite of non-invasive technologies helps clinicians identify stenoses in the coronary arteries (RoadMap™Analysis), assess coronary blood flow (FFRCT Analysis), and characterize and quantify coronary atherosclerosis (Plaque Analysis). To date, more than 500 peer-reviewed publications have validated our approach and, more importantly, our technologies have helped clinicians diagnose and manage over 200,000 patients. For more information, visit and connect on Twitter and LinkedIn.


Linly Ku


Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.